Report overview
Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Drugs. This report contains market size and forecasts of Neurodegenerative Drugs in global, including the following market information:
Global Neurodegenerative Drugs Market Revenue, 2018-2023, 20242035, ($ millions)
Global Neurodegenerative Drugs Market Sales, 2018-2023, 20242035, (MT)
Global top five Neurodegenerative Drugs companies in 2022 (%)
The global Neurodegenerative Drugs market was valued at US$ 118360 million in 2022 and is projected to reach US$ 174250 million by 2029, at a CAGR of 5.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
NMDA Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neurodegenerative Drugs include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi and GlaxoSmithKline, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neurodegenerative Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurodegenerative Drugs Market, by Type, 2018-2023, 20242035 ($ Millions) & (MT)
Global Neurodegenerative Drugs Market Segment Percentages, by Type, 2022 (%)
NMDA
SSRIs
Dopamine Inhibitors
Global Neurodegenerative Drugs Market, by Application, 2018-2023, 20242035 ($ Millions) & (MT)
Global Neurodegenerative Drugs Market Segment Percentages, by Application, 2022 (%)
Parkinson?s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer?s Disease
Global Neurodegenerative Drugs Market, By Region and Country, 2018-2023, 20242035 ($ Millions) & (MT)
Global Neurodegenerative Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neurodegenerative Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neurodegenerative Drugs revenues share in global market, 2022 (%)
Key companies Neurodegenerative Drugs sales in global market, 2018-2023 (Estimated), (MT)
Key companies Neurodegenerative Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurodegenerative Drugs, market overview.
Chapter 2: Global Neurodegenerative Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neurodegenerative Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
